Αρχική World News Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive... World News Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer Από Ogkologos - 17 Αυγούστου, 2026 157 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PSMAddition study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple... 15 Σεπτεμβρίου, 2023 Family Starts “Dancing While Cancering” To Honor Their Daughter’s Joyful Memory. 9 Οκτωβρίου, 2019 Pursuing precision medicine in a flagship lung cancer trial 15 Ιουλίου, 2020 The EPA’s Limitations On This Toxic Pesticide Put Children At Risk... 5 Φεβρουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Truck Driver Saves People From Bus Fire On Christmas Eve 11 Sun Safety Myths Debunked Our 10 top tips to help you talk about cancer FDA Grants Accelerated Approval to Selpercatinib for Paediatric Patients Two Years...
